Researchers from the University of Alberta have discovered a possibly dangerous side effects associated with the famous vascular drug.
In a study published a month ago Through the prestigious magazines of the American College of Cardiology (JACC), the research team led by Jason Dyck, a professor of distinguished pediatrics and head of Canada in molecular medicine, sought to determine whether there are any links between muscle loss, skeleton and Osimb.
Using an advanced experimental approach, researchers conducted experiments on mice that simulate the nutritional conditions similar to those adopted by individuals who use these medications to lose weight.
The results were both wonderful and consistent. Over a period of only three weeks, mice showed a 8.2 % decrease in muscle mass, skeleton and lean body weight. Perhaps more anxious, muscle loss was not limited to structural muscles because it also extended to the heart muscles, which affects both obesity and lean.
“Given the increasing number of people who take this medicine who do not have cardiovascular diseases or who have not been classified as obese, we suggest that the structure of the heart and function be carefully evaluated in previous and continuous clinical studies,” the authors of the study confirmed.
The use of OzemPIC can lead to vulnerable immunity
Contrary to common belief, the muscles are not only responsible for movement and physical strength. They are complex structures that play a decisive role in the health of human metabolism, the performance of the immune system, and physiological functions.
The famous dietary expert Carla Brado of Alberta University presented critical visions of the effects of muscle loss. A paper published in Lancet confirmed that up to 40 % of weight loss can be muscle mass.
This is a disturbing percentage that exceeds the result of a traditional diet or natural aging.
Long -term consequences for severe muscle loss. First, they are responsible for creating amino acid reserves that help the body deal with stress, injury or disease rings.
Moreover, it plays a major role in managing the level of sugar in the body and it is decisive to prevent metabolic diseases such as diabetes. In addition, they send signals to the immune system through specialized particles called Myokines.
If OzemPIC produces muscle loss as researchers seem to say, this may mean that the drug can reduce the patient’s immunity, increase its sensitivity to infections, and even paralyze the wound recovery.
“If people are prescribed these medications, the benefits should likely exceed risks,” DYCK confirmed.
He continued, “However, the increasing number of people who may take these drugs who do not meet eligibility standards and who are not in danger have a different account to form the risks that should be aware.”
The research study also indicated that the decrease in the muscles associated with these drugs can exacerbate cases such as sarcopia obesity. This is a condition of high body fat and low structural muscle mass, which is known to contribute to harmful health results, including an increased risk of cardiovascular disease and high death rates.
Elie Lily and Novo Nordsk were subjected to lawsuits amid unveiled side effects
These new studies are on the surface at a point when the pharmaceutical companies that make these drugs that make weight are multiple lawsuits from patients who have suffered from complications and harmful side effects when using a poultryide.
Also read: The lawsuit: Here is what you need to know
Elie Lily and Novo Nordsk have been subjected to legal procedures currently supervised by the American boycott judge, Karen S. Marson. Their drugs were linked to weight, Osepak, Wujovi, Mounjaro have been linked to stomach accidents, marinacular bowel syndrome, necrosis pancreatitis, gallbladder disease, deep vein clotting, and pulmonary violation.
Prosecutors argue that the pharmaceutical manufacturers have given the priority of financial gains for comprehensive safety and patients and patients effectively exposed to great health risks without providing sufficient warnings about the long -term consequences of the provision of these drugs.
GLP-1 was used to treat diabetes, then OzemPIC came
The side effects associated with the use of the Glp -1 RAS are the main theme for studying through medical research at the present time. This substance has been developed as a treatment for type 2 diabetes because it helps patients control blood sugar levels.
However, the syilotide, the active component of other similar drugs or medicines, was considered an innovation in the pharmaceutical industry as the development of the GLP-1 in a weight loss solution.
The ability of the drug to suppress appetite and adjust metabolism made it unusually common and exceeded its initial medical purpose.
In light of these results, both researchers and medical professionals urge the audience to adopt a size approach to the use of drugs such as OzemPic for weight management purposes.
Also read: Ways to help you lose weight – prove scientifically
Nutrition and exercise were determined as critical ingredients for a balanced approach. Researchers, such as Prado, emphasize the importance of eating high -quality protein, vitamins and essential minerals, and targeted resistance training.
Protein supplements may also be included in the patient’s diet to ensure the body gets the necessary nutrients while specific exercise systems can help reduce the collapse of the muscles associated with OzemPIC.
More studies are needed to assess long -term consequences to use OzemPIC
The University of Alberta categorically does not condemn these drugs, but it causes researchers to study the drug and its side effects more.
The authors emphasize that although no immediate harmful functional effects on test themes are not observed, the possible effect on the long -term use of the drug must now be carefully evaluated.
Jason Dyck and his team strongly recommended an accurate evaluation of the structure of the heart and function in continuous and future clinical studies, especially for individuals without the pre -existing cardiovascular conditions or those that were not classified as obesity.
As scientific and medical societies continue to investigate these complex drugs, patients are urged to maintain open and transparent dialogues with health care providers.
The study highlights the importance of implementing a personal approach that carefully weighs the risks and potential benefits before prescribing medications such as OzemPIC.
